ADAR1 Capital Management, LLC
Position in KPTI — Karyopharm Therapeutics Inc.
CIK 1940272
AUSTIN, TX
Position in KPTI
as of Mar 31, 2026
· filed May 18, 2026
Position Value
$761,619
+$393,619 QoQ
Shares Held
136,736
+173.5% QoQ
Ownership
0.603%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in KPTI Over Time
Shares Held
Position Value (USD)
Derivatives in KPTI
reported options exposure · as of Mar 31, 2026CallValue
$1,142,964
CallShares
205,200
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026ADAR1 Capital Management, LLC holds $1,358,769,126 across 212 Biotechnology names. KPTI ranks #123 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
1,394,019 | $155,224,015 | |
| 2 | PTGX |
Protagonist Therapeutics, Inc
|
994,119 | $104,780,142 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
3,285,906 | $91,019,596 | |
| 4 | IMVT |
Immunovant, Inc.
|
2,679,010 | $66,546,608 | |
| 5 | TERN |
Terns Pharmaceuticals, Inc.
|
914,699 | $48,222,931 | |
| 6 | CYTK |
Cytokinetics Inc
|
632,556 | $41,691,765 | |
| 7 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
1,139,331 | $41,380,501 | |
| 8 | DNLI |
Denali Therapeutics Inc.
|
1,871,455 | $35,931,936 |
All Filings in KPTI
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,142,964 | 205,200 | Call | Sole | 2026-05-18 | |
| 2026-03-31 | $761,619 | 136,736 | Shares | Sole | 2026-05-18 | |
| 2025-12-31 | $368,000 | 50,000 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $163,500 | 25,000 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||